Comparison of the bis‐intercalating complexes formed between either ditercalinium or a flexible analogue and d(CpGpCpG)2 or d(TpTpCpGpCpGpApA)2 minihelices: 1H‐ and 31P‐nmr analyses
暂无分享,去创建一个
M. Delepierre | B. Roques | M. Le Bret | J. Igolen | C. Garbay‐Jaureguiberry | Joël Pothier | M. Barsi
[1] A. Rich,et al. Drug-induced DNA repair: X-ray structure of a DNA-ditercalinium complex. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[2] B. Roques,et al. Recognition by the DNA repair system of DNA structural alterations induced by reversible drug-DNA interactions. , 1990, Anti-cancer drug design.
[3] S. Brown,et al. Selective alteration of mitochondrial function by Ditercalinium (NSC 335153), a DNA bisintercalating agent. , 1990, Biochemical pharmacology.
[4] M. Delepierre,et al. Bisintercalation of ditercalinium into a d(CpGpApTpCpG)2 minihelix: A 1H‐ and 31P‐NMR study , 1989, Biopolymers.
[5] M. Delepierre,et al. Intercalative binding of ditercalinium to d(CpGpCpG)2: a theoretical study. , 1989, Journal of biomolecular structure & dynamics.
[6] M. Delepierre,et al. 1H and 31P nuclear magnetic resonance studies of the differences in DNA deformation induced by anti-tumoral 7H-pyrido[4,3-c]carbazole dimers. , 1989, Journal of molecular biology.
[7] B. Roques,et al. The noncovalent complex between DNA and the bifunctional intercalator ditercalinium is a substrate for the UvrABC endonuclease of Escherichia coli. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Patel,et al. Antitumour drug–DNA interactions: NMR studies of echinomycin and chromomycin complexes , 1989, Quarterly Reviews of Biophysics.
[9] B. Roques,et al. Acridine dimers: influence of the intercalating ring and of the linking-chain nature on the equilibrium and kinetic DNA-binding parameters. , 1989, European journal of biochemistry.
[10] M. Delepierre,et al. 1H‐nmr studies of a monointercalating drug into a d[CpGpCpG]2 minihelix , 1987, Biopolymers.
[11] B. Roques,et al. Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent. , 1988, Cancer research.
[12] M. Delepierre,et al. Study of the bisintercalation of the antitumor drug ditercalinium by 31P‐nmr , 1988, Biopolymers.
[13] B. Roques,et al. Asymmetrical bisintercalators as potential antitumor agents. , 1988, Journal of medicinal chemistry.
[14] B. Roques,et al. Induction of an abortive and futile DNA repair process in E. coli by the antitumor DNA bifunctional intercalator, ditercalinium: role in polA in death induction. , 1988, Nucleic acids research.
[15] M. Delepierre,et al. A general procedure for assigning the 31P spectra of drug-oligonucleotide complexes. , 1988, Journal of biomolecular structure & dynamics.
[16] B. Reid. Sequence-specific assignments and their use in NMR studies of DNA structure , 1987, Quarterly Reviews of Biophysics.
[17] M. Delepierre,et al. Bisintercalation of ditercalinium into a d[CpGpCpG]2 minihelix: Structure and dynamics aspects—a 400‐MHz 1H‐nmr study , 1987, Biopolymers.
[18] M. Delepierre,et al. DNA bis-intercalators as new anti-tumour agents: modulation of the anti-tumour activity by the linking chain rigidity in the ditercalinium series. , 1987, Anti-cancer drug design.
[19] M. Delepierre,et al. Geometry of the antitumor drug ditercalinium bisintercalated into d(CpGpCpG)2 by 1H NMR. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[20] B. Roques,et al. Synthesis of 11H-pyridocarbazoles and derivatives. Comparison of their DNA binding and antitumor activity with those of 6H- and 7H-pyridocarbazoles. , 1986, Journal of medicinal chemistry.
[21] Ad Bax,et al. MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy , 1985 .
[22] K. Houk,et al. Transition structures for additions of lithium hydride and methyllithium to ethylene and acetylene , 1985 .
[23] W. Denny,et al. Proton NMR study of the binding of bis(acridines) to d(AT)5.cntdot.d(AT)5. 2. Dynamic aspects , 1985 .
[24] B. Roques,et al. Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L 1210 cells. , 1984, Cancer research.
[25] David G. Gorenstein,et al. Phosphorus-31 NMR : principles and applications , 1984 .
[26] K. Wüthrich,et al. Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. , 1983, Biochemical and biophysical research communications.
[27] Ray Freeman,et al. Broadband heteronuclear decoupling , 1982 .
[28] B. Roques,et al. DNA intercalating compounds as potential antitumor agents. 1. Preparation and properties of 7H-pyridocarbazoles. , 1980, Journal of medicinal chemistry.
[29] P. Dessen,et al. Deoxyribonucleic acid bifunctional intercalators: kinetic investigation of the binding of several acridine dimers to deoxyribonucleic acid. , 1979, Biochemistry.
[30] B. Roques,et al. DNA bifunctional intercalators: antileukemic activity of new pyridocarbazole dimers. , 1979, Biochemical pharmacology.
[31] B. Roques,et al. DNA Bifunctional intercalators. 2. Fluorescence properties and DNA binding interaction of an ethidium homodimer and an acridine ethidium heterodimer. , 1978, Biochemistry.
[32] B. Roques,et al. DNA bifunctional intercalators. I. Synthesis and conformational properties of an ethidium homodimer and of an acridine ethidium heterodimer. , 1978, Biochemistry.
[33] M Le Bret,et al. DNA polyintercalating drugs: DNA binding of diacridine derivatives. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Le Pecq,et al. The change of the torsion of the DNA helix caused by intercalation. II. Measurement of the relative change of torsion induced by various intercalating drugs. , 1971, Biochimie.
[35] H. Eisenberg,et al. Viscosity and sedimentation study of sonicated DNA–proflavine complexes , 1969 .